Vitiligo in a Case of Systemic Lupus Erythematosus on Long-Term Hydroxychloroquine: A Coincidence or Consequence?
Malaysian Journal of Dermatology · 2025
DOI: 10.4103/mjd.mjd_17_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Malaysian Journal of Dermatology, 2025. Verfasst von Shrayan Pal und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Systemic lupus erythematosus (SLE) is an autoimmune disorder that occurring due to triggers such as ultraviolet radiation and drugs, involving both innate and adaptive immune systems. It is usually treated with topical and systemic corticosteroids, antimalarials such as hydroxychloroquine (HCQ) and photoprotection. Vitiligo is also an autoimmune disorder of T-cell driven melanocyte destruction due to genetic predisposition, oxidative stress and drugs. Here, we describe a case of SLE who developed vitiligo over cutaneous lupus lesions after long-term HCQ therapy. A 25-year-old female presented with bilaterally symmetrical erythematous scaly plaques over upper and lower limbs with a malar rash for 1 year with a history of fever, arthralgia, myalgia and oral ulcer. The anti-nuclear antibody titre was >1:160. The haemoglobin value was 8.9 g/dl. Biopsy of the lesion showed perivascular and periappendageal lymphocytic infiltrates, interface dermatitis and vacuolar degeneration of basal cells. She was diagnosed as a case of SLE with papulosquamous type subacute cutaneous lupus lesion and started on oral HCQ 200 mg twice daily. After 2 years, she developed depigmented patches over the dorsum of hands and feet which was diagnosed as vitiligo clinically and by dermoscopy. Association of lupus erythematosus and vitiligo has been described in literature based on theory of immunocompromised cutaneous district and shared inflammatory pathways involving plasmacytoid dendritic cells. Moreover, long-term HCQ can contribute to depigmentation as it interferes with melanogenesis. Investigations are needed to rule out multiple autoimmune syndrome and autoimmune polyglandular syndrome. In this case, phototherapy should be avoided as a treatment modality for vitiligo, as it can aggravate lupus.
Zitieren
APA
Pal, S., & Maiti, S. (2025). Vitiligo in a Case of Systemic Lupus Erythematosus on Long-Term Hydroxychloroquine: A Coincidence or Consequence?. Malaysian Journal of Dermatology. https://doi.org/10.4103/mjd.mjd_17_25
Vancouver
Pal S, Maiti S. Vitiligo in a Case of Systemic Lupus Erythematosus on Long-Term Hydroxychloroquine: A Coincidence or Consequence?. Malaysian Journal of Dermatology. 2025. doi:10.4103/mjd.mjd_17_25
BibTeX
@article{Pal2025,
author = {Pal, Shrayan and Maiti, Swarnali},
title = {Vitiligo in a Case of Systemic Lupus Erythematosus on Long-Term Hydroxychloroquine: A Coincidence or Consequence?},
journal = {Malaysian Journal of Dermatology},
year = {2025},
doi = {10.4103/mjd.mjd_17_25}
}
EUVIMED